2021 Global Antibiotics Partnering Directory – Top Deals by Value – ResearchAndMarkets.com

2021 Global Antibiotics Partnering Directory – Top Deals by Value – ResearchAndMarkets.com




2021 Global Antibiotics Partnering Directory – Top Deals by Value – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Antibiotics Partnering Terms and Agreements 2010 to 2021” report has been added to ResearchAndMarkets.com’s offering.

The Global Antibiotics Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 300 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2021 includes:

  • Trends in antibiotics dealmaking in the biopharma industry since 2010
  • Analysis of antibiotics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 300 antibiotics deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active antibiotics dealmakers since 2010
  • The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Global Antibiotics Partnering Terms and Agreements 2010 to 2021 provides the reader with the following key benefits:

  • In-depth understanding of antibiotics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 300 antibiotics deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
  • Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading antibiotics deals by value since 2010
  • Identify the most active antibiotics dealmakers since 2010
  • Detailed access to actual antibiotics contracts enter into by the leading twenty five big pharma and big biotech companies
  • Insight into the terms included in a antibiotics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Companies Mentioned

  • Oxford Drug Design
  • Gilead Sciences
  • MD Anderson Cancer Center
  • Biomedical Advanced Research and Development Authority
  • Lysando
  • Warp Drive Bio
  • Centre for Drug Research and Development (CDRD)
  • InSite Vision
  • France’s General Directorate for Armaments
  • Q-linea AB
  • Basilea Pharmaceutica
  • European Commission
  • European Union
  • XBiotech
  • QureTech Bio
  • AnnaMed
  • Dr. Reddy’s Laboratories
  • NovaMedica
  • The Medicines Company
  • The Regents of the University of California
  • Paratek Pharmaceuticals
  • Stiefel Laboratories
  • Decibel Therapeutics
  • NacuGen Therapeutics
  • Quotient Bioresearch
  • Emergent BioSolutions
  • Novasep
  • Polypeptide Laboratory
  • Premier Inc
  • Optimer Pharmaceuticals
  • Auspherix
  • Strides Arcolab
  • Synthetic Biologics
  • Medimetriks
  • SINTEF
  • Dana-Farber Cancer Institute
  • Finorga
  • Allergan

For more information about this report visit https://www.researchandmarkets.com/r/de95j1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900